BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36252317)

  • 1. Details and outcomes of a large cohort of MOG-IgG associated optic neuritis.
    Chen JJ; Flanagan EP; Bhatti MT; Tisavipat N; Jamali S; Kunchok A; Eggenberger ER; Nome MD; Sotirchos ES; Vasileiou ES; Henderson AD; Arnold AC; Bonelli L; Seleme N; Mejia-Vergara AJ; Moss HE; Padungkiatsagul T; Stiebel-Kalish H; Lotan I; Wilf-Yarkoni A; Hellmann MA; Vuppala A; Hodge D; Pittock SJ
    Mult Scler Relat Disord; 2022 Dec; 68():104237. PubMed ID: 36252317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?
    Stiebel-Kalish H; Hellmann MA; Mimouni M; Paul F; Bialer O; Bach M; Lotan I
    Neurol Neuroimmunol Neuroinflamm; 2019 Jul; 6(4):e572. PubMed ID: 31355308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome.
    Chen JJ; Flanagan EP; Jitprapaikulsan J; López-Chiriboga ASS; Fryer JP; Leavitt JA; Weinshenker BG; McKeon A; Tillema JM; Lennon VA; Tobin WO; Keegan BM; Lucchinetti CF; Kantarci OH; McClelland CM; Lee MS; Bennett JL; Pelak VS; Chen Y; VanStavern G; Adesina OO; Eggenberger ER; Acierno MD; Wingerchuk DM; Brazis PW; Sagen J; Pittock SJ
    Am J Ophthalmol; 2018 Nov; 195():8-15. PubMed ID: 30055153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis.
    Jitprapaikulsan J; Chen JJ; Flanagan EP; Tobin WO; Fryer JP; Weinshenker BG; McKeon A; Lennon VA; Leavitt JA; Tillema JM; Lucchinetti C; Keegan BM; Kantarci O; Khanna C; Jenkins SM; Spears GM; Sagan J; Pittock SJ
    Ophthalmology; 2018 Oct; 125(10):1628-1637. PubMed ID: 29716788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visual Outcomes Following Plasma Exchange for Optic Neuritis: An International Multicenter Retrospective Analysis of 395 Optic Neuritis Attacks.
    Chen JJ; Flanagan EP; Pittock SJ; Stern NC; Tisavipat N; Bhatti MT; Chodnicki KD; Tajfirouz DA; Jamali S; Kunchok A; Eggenberger ER; Nome MAD; Sotirchos ES; Vasileiou ES; Henderson AD; Arnold AC; Bonelli L; Moss HE; Navarro SEV; Padungkiatsagul T; Stiebel-Kalish H; Lotan I; Wilf-Yarkoni A; Danesh-Meyer H; Ivanov S; Huda S; Forcadela M; Hodge D; Poullin P; Rode J; Papeix C; Saheb S; Boudot de la Motte M; Vignal C; Hacohen Y; Pique J; Maillart E; Deschamps R; Audoin B; Marignier R
    Am J Ophthalmol; 2023 Aug; 252():213-224. PubMed ID: 36822570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis.
    Chen JJ; Bhatti MT
    Curr Opin Neurol; 2020 Feb; 33(1):47-54. PubMed ID: 31743235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in Clinical Features of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis in White and Asian Race.
    Padungkiatsagul T; Chen JJ; Jindahra P; Akaishi T; Takahashi T; Nakashima I; Takeshita T; Moss HE
    Am J Ophthalmol; 2020 Nov; 219():332-340. PubMed ID: 32681910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical difference after the first optic neuritis between aquaporin-4-IgG-associated and myelin oligodendrocyte glycoprotein-IgG-associated disorders.
    Masuda H; Mori M; Yokouchi H; Uzawa A; Uchida T; Muto M; Ohtani R; Aoki R; Yamamoto S; Kuwabara S
    J Neurol; 2022 Apr; 269(4):1996-2003. PubMed ID: 34455476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute Optic Neuropathy in Older Adults: Differentiating Between MOGAD Optic Neuritis and Nonarteritic Anterior Ischemic Optic Neuropathy.
    Tisavipat N; Stiebel-Kalish H; Palevski D; Bialer OY; Moss HE; Chaitanuwong P; Padungkiatsagul T; Henderson AD; Sotirchos ES; Singh S; Salman AR; Tajfirouz DA; Chodnicki KD; Pittock SJ; Flanagan EP; Chen JJ
    Neurol Neuroimmunol Neuroinflamm; 2024 May; 11(3):e200214. PubMed ID: 38547435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial.
    Chen JJ; Tobin WO; Majed M; Jitprapaikulsan J; Fryer JP; Leavitt JA; Flanagan EP; McKeon A; Pittock SJ
    JAMA Ophthalmol; 2018 Apr; 136(4):419-422. PubMed ID: 29470571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies.
    Hassan MB; Stern C; Flanagan EP; Pittock SJ; Kunchok A; Foster RC; Jitprapaikulsan J; Hodge DO; Bhatti MT; Chen JJ
    Am J Ophthalmol; 2020 Dec; 220():110-114. PubMed ID: 32707199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical profile and challenges faced in the management of optic neuritis: the Indian scenario.
    Kaushik M; Shah VM; Murugesan S; Mani KK; Vardharajan S
    Int Ophthalmol; 2024 Mar; 44(1):138. PubMed ID: 38488890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinal Nerve Fiber Layer May Be Better Preserved in MOG-IgG versus AQP4-IgG Optic Neuritis: A Cohort Study.
    Stiebel-Kalish H; Lotan I; Brody J; Chodick G; Bialer O; Marignier R; Bach M; Hellmann MA
    PLoS One; 2017; 12(1):e0170847. PubMed ID: 28125740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated myelin oligodendrocyte glycoprotein antibody-associated optic neuritis in adults: The importance of age of onset and prognosis-related radiological features.
    Zhao J; Chen X; Zhang J; Liu L; Wang J; Zhu L
    Mult Scler Relat Disord; 2024 May; 85():105518. PubMed ID: 38447395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcomes of first-ever episode of severe optic neuritis.
    Galetta K; Ryan S; Manzano G; Chibnik LB; Balaban D; Prasad S; Chwalisz BK; Salazar-Camelo A; Conway S; Levy M; Matiello M
    Mult Scler Relat Disord; 2022 Oct; 66():104020. PubMed ID: 35839615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resolution of myelin oligodendrocyte glycoprotein (MOG)-IgG optic neuritis without treatment.
    Vosoughi AR; Micieli JA
    Mult Scler Relat Disord; 2020 Nov; 46():102456. PubMed ID: 32853896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiologic and Clinical Characteristics of Optic Neuritis in Japan.
    Ishikawa H; Kezuka T; Shikishima K; Yamagami A; Hiraoka M; Chuman H; Nakamura M; Hoshi K; Goseki T; Mashimo K; Mimura O; Yoshitomi T; Tanaka K;
    Ophthalmology; 2019 Oct; 126(10):1385-1398. PubMed ID: 31196727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease.
    Akaishi T; Himori N; Takeshita T; Misu T; Takahashi T; Takai Y; Nishiyama S; Fujimori J; Ishii T; Aoki M; Fujihara K; Nakazawa T; Nakashima I
    Mult Scler Relat Disord; 2021 Nov; 56():103222. PubMed ID: 34461572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.